In high (history of thrombosis or age >60 with JAK2 V617F)- and intermediate (age >60, no JAK2 mutation, and no history of thrombosis)-risk ET, cytoreductive therapy is mandatory to obtain both symptom relief and reduction in cardiovascular risk [18]. Here, JAK2 is linked to Venous thrombosis.